{"id":"NCT00905255","sponsor":"Sanofi","briefTitle":"GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation in Monotherapy (GETGOAL-MONO Japan LTS)","officialTitle":"A Randomized, Open Label, Parallel-group (One-step Titration and Two-step Titration), Multicenter 52-Week Study Followed by a 24-Week Extension Assessing the Safety and Tolerability of AVE0010 Monotherapy in Patients With Type 2 Diabetes","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-05","primaryCompletion":"2011-01","completion":"2011-01","firstPosted":"2009-05-20","resultsPosted":"2016-12-21","lastUpdate":"2016-12-21"},"enrollment":69,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Diabetes Mellitus, Type 2"],"interventions":[{"type":"DRUG","name":"Lixisenatide (AVE0010)","otherNames":[]},{"type":"DEVICE","name":"Pen auto-injector","otherNames":["OptiClikÂ®"]}],"arms":[{"label":"Lixisenatide (Two-step Titration)","type":"EXPERIMENTAL"},{"label":"Lixisenatide (One-step Titration)","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to compare the benefits and risks of lixisenatide (AVE0010) used as 2-step initiation regimen and 1-step initiation regimen in Japan, over a period of 24 weeks of treatment, followed by an extension up to Week 76.\n\nThe primary objective of this study is to evaluate the safety of lixisenatide once daily treatment in monotherapy at Week 24 by a descriptive comparison of a 1-step initiation and a 2-step initiation regimen in patients with type 2 diabetes in Japan.\n\nThe secondary objectives are to assess the overall safety of lixisenatide once daily treatment in monotherapy at Week 52 and Week 76; to assess the effects of lixisenatide on glycosylated hemoglobin (HbA1c) reduction at Week 52 and Week 76, body weight, and fasting plasma glucose (FPG); to assess pharmacokinetics (PK) and anti-lixisenatide antibody development.","primaryOutcome":{"measure":"Overview of Adverse Event Profile (Treatment Emergent Adverse Events) of the One-Step and Two-Step Titration Arms Assessed Through Adverse Events Collection and Vital Signs, Electrocardiogram (ECG) and Laboratory Monitoring","timeFrame":"First dose of study drug up to 3 days after the last dose of study drug at Week 24 or early withdrawal","effectByArm":[{"arm":"Lixisenatide (Two-step Titration)","deltaMin":81.8,"sd":null},{"arm":"Lixisenatide (One-step Titration)","deltaMin":88.9,"sd":null}],"pValues":[]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":25},"locations":{"siteCount":1,"countries":["Japan"]},"refs":{"pmids":["26342556"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":33},"commonTop":["Nausea","Nasopharyngitis","Decreased appetite","Abdominal discomfort","Hypoglycaemia"]}}